Develops therapies for Alzheimer's disease and other neurodegenerative disorders, focusing on synaptic health.
Synaptogenix, Inc. is a dynamic biopharmaceutical firm actively advancing its product candidates through pre-clinical and clinical development stages. Central to its mission is the development of Bryostatin-1, a promising drug candidate aimed at treating Alzheimer's disease. Beyond Alzheimer's, the company is exploring Bryostatin's potential therapeutic applications for various neurodegenerative and cognitive disorders, including fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease.
Establishing strategic partnerships has been integral to Synaptogenix, Inc.'s growth and innovation. The company holds licensing agreements with prestigious institutions such as Stanford University, Icahn School of Medicine at Mount Sinai, and The Board of Trustees of the Leland Stanford Junior University. These collaborations bolster its research capabilities and expand its reach in exploring novel treatments for complex neurological conditions.
Founded in 2012 and headquartered in New York, New York, Synaptogenix, Inc. continues to drive advancements in neuroscience with a commitment to pioneering therapies that address significant unmet medical needs. The company's dedication to innovative research and strategic partnerships positions it at the forefront of developing transformative treatments for neurological diseases, aiming to improve outcomes and quality of life for patients globally.